Edgewise sells muscular dystrophy drug to Servier for up to $2.65B
What's the deal? Edgewise Therapeutics has agreed to sell sevasemten — its muscular dystrophy drug and related business — to French pharmaceutical group ServierDealroom has a profile for this one. Try Dealroom → for $1.55B in upfront cash, plus up to $1.1B in regulatory and commercial milestones. The deal's total potential value: $2.65B.
The Boulder, Colorado-based biotech announced the definitive agreement on 1 June 2026. Following the transaction's close, Edgewise will pivot to become a purely cardiovascular-focused company, centring its efforts on its remaining pipeline asset, EDG-7500, a treatment for hypertrophic cardiomyopathy (HCM).
Why now? Edgewise is on track to report 12-week data from its CIRRUS-HCM Part D trial in Q2 2026 — a critical readout for the company's cardiac programme. The upfront proceeds from the Servier deal are expected to fully fund EDG-7500 development through potential approval, giving Edgewise a runway to advance its lead cardiovascular candidate without needing to raise additional capital.
Servier, an independent pharma group governed by a foundation, gains a late-stage muscular dystrophy asset — a therapeutic area where unmet medical need remains high, particularly in Duchenne and Becker muscular dystrophy.
What could go wrong? Edgewise is effectively betting its future on a single cardiovascular programme. If EDG-7500 trial data disappoints or the drug fails to win regulatory approval, the company would be left with a strong balance sheet but a thin pipeline. The $1.1B in milestone payments also depends on sevasemten hitting specific regulatory and commercial targets under Servier's stewardship — outcomes Edgewise will no longer control.
The signal: The deal reflects a broader trend in biotech: mid-cap companies narrowing their focus and selling non-core assets at premium valuations to fund their most promising programmes. Rather than spreading resources across two therapeutic areas, Edgewise is concentrating capital and management attention on cardiovascular disease — a massive, well-funded market.
For Servier, the acquisition fits a pattern of European pharma groups building neuromuscular portfolios through bolt-on deals. The transaction also underscores sustained buyer appetite for clinical-stage rare disease assets, even as broader biotech funding remains volatile.
Read more: Edgewise Therapeutics investor release
